Daniel Drucker, a pioneer in GLP-1 receptor–agonist research, discusses the history of the drugs, their wide-ranging benefits, and how they might benefit patients with cancer. On April 28, 2005, the ...

Renowned scientist Douglas Hanahan, PhD, discusses the legacy of The Hallmarks of Cancer, the challenge of adaptive resistance, and how insights into the tumor microenvironment and cancer neuroscience ...

St. Jude Children's Research Hospital, Memphis, TN.

Search for other works by this author on: ...

A high-resolution map of how protein organization inside the cell provides a platform for interrogating the way cancer mutations disrupt entire protein assemblies—not just individual genes. By ...

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Priti Bandi, Risk Factors and Screening Research, Surveillance and Health Equity Science, ...

W. Kimryn Rathmell, MD, PhD, has accepted the role as CEO of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. She was ...

The NIH will not award research grants to universities with diversity, equity, and inclusion (DEI) programs or boycotts of Israel, including those against Israeli companies or those that do business ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Search for other works by this author on: ...

Search for other works by this author on: ...

Seda Pharmaceutical Development Services, Stockport, United Kingdom.